Nov 10, 2017
Today is Day 1 of tumor treatment with the C-Lectin Receptor nanocarrier (the TargoSphere) with encapsulated Curcumin alone and in combination with the mouse Immune Checkpoint Inhibitor.
Treatment will continue daily for 14 days and tumor growth will be measured at regular intervals. We will keep you informed of results as the study progresses.
Your contributions have made this a reality, and we thank you.
The Team
Frank, NYRAD, and 4 others like this.
We hypothesize that targeted delivery of Curcumin to antigen presenting cells in the immune system can suppress tumor growth for a variety of cancers. This study will examine tumor responses to Curcumin in a colon cancer mouse model when given alone or in combination with an FDA-approved immune Checkpoint Inhibitor. Positive results will lead to Fast-Track FDA applications for human and companion pet animal cancer trials.
Ostomy bags are a daily medical necessity for 15 million people globally. However, these bags often delaminate...
We are developing a frugal diagnostic for urogenital schistosomiasis, a neglected tropical disease that...
As of mid-2019, 87 countries have had or still have Zika cases, underlining the importance of this infectious...
2 comments